Nephrol Dial Transplant (2002) 17: 1327-1332
© 2002 European Renal Association-European Dialysis and Transplant Association
Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies
1 University of Melbourne Departments of Medicine at St Vincent's Hospital, Fitzroy, 2 Austin and Repatriation Medical Centre, Heidelberg, Australia and 3 The Haartman Institute, Division of Bacteriology and Immunology, University of Helsinki, Finland
Background. Mutations in the gene coding for the podocyte slit-pore membrane protein, nephrin, are responsible for the Finnish-type congenital nephrotic syndrome. The present study sought to examine whether nephrin expression may also be altered in experimental diabetes, and how such changes related to the development of proteinuria. In addition, the study also sought to examine nephrin expression in animals treated with different anti-proteinuric therapies.
Methods. Nephrin gene expression and localization were examined in rats with streptozotocin-induced diabetes at 6 months duration (proteinuric phase) and at 7 days (pre-proteinuric phase). In addition, the effects of anti-proteinuric drug therapies were also assessed in long-term diabetic rats, treated with either the angiotensin-converting enzyme inhibitor perindopril, or the blocker of advanced glycation end-product formation, aminoguanidine. Nephrin expression was determined using quantitative real-time PCR and in situ hybridization.
Results. When compared with control animals, nephrin expression was reduced in the late proteinuric phase (45% reduction vs controls, P<0.01) but not in the early, pre-proteinuric phase of experimental diabetic nephropathy. While ACE inhibition and aminoguanidine both reduced proteinuria, only the former attenuated the diabetes-associated reduction in nephrin expression.
Conclusions. These findings suggests that reduction in nephrin may be a determinant of glomerular hyperpermeability in diabetic nephropathy. Attenuation of these changes with ACE inhibition suggest that this mechanism may contribute to the anti-proteinuric effects of this, but not all classes of drug which reduce urinary protein in diabetic nephropathy.
Keywords: advanced glycation end products; angiotensin II; diabetes; nephrin; podocyte; proteinuria
Correspondence and offprint requests to: Richard E. Gilbert MD, PhD, University of Melbourne, Department of Medicine, St Vincent’s Hospital, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia. Email: gilbert{at}medstv.unimelb.edu.au
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Kelly, A. J. Edgley, Y. Zhang, K. Thai, S. M. Tan, A. J. Cox, A. Advani, K. A. Connelly, C. I. Whiteside, and R. E. Gilbert Protein kinase C-{beta} inhibition attenuates the progression of nephropathy in non-diabetic kidney disease Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1782 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Otaki, N. Miyauchi, M. Higa, A. Takada, T. Kuroda, F. Gejyo, F. Shimizu, and H. Kawachi Dissociation of NEPH1 from nephrin is involved in development of a rat model of focal segmental glomerulosclerosis Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1376 - F1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wang, F. M.-M. Lai, K.-B. Lai, K.-M. Chow, B. C.-H. Kwan, P. K.-T. Li, and C.-C. Szeto Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker Eur. J. Endocrinol., March 1, 2008; 158(3): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nakhoul, E. Khankin, A. Yaccob, H. Kawachi, T. Karram, H. Awaad, N. Nakhoul, A. Hoffman, and Z. Abassi Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome Am J Physiol Renal Physiol, March 1, 2008; 294(3): F628 - F637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Han, S. Y. Park, J.-J. Li, S. J. Kwak, D. S. Jung, H. Y. Choi, J. E. Lee, S. J. Moon, D. K. Kim, D.-S. Han, et al. Glomerular glucocorticoid receptor expression is reduced in late responders to steroids in adult-onset minimal change disease Nephrol. Dial. Transplant., January 1, 2008; 23(1): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Advani, D. J. Kelly, S. L. Advani, A. J. Cox, K. Thai, Y. Zhang, K. E. White, R. M. Gow, S. M. Marshall, B. M. Steer, et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions PNAS, September 4, 2007; 104(36): 14448 - 14453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nakajo, J. Khoshnoodi, H. Takenaka, E. Hagiwara, T. Watanabe, H. Kawakami, R. Kurayama, Y. Sekine, F. Bessho, S. Takahashi, et al. Mizoribine Corrects Defective Nephrin Biogenesis by Restoring Intracellular Energy Balance J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2554 - 2564. [Full Text] [PDF]
|
|
|
|
|
|
P. Aaltonen, J. Rinta-Valkama, A. Patari, P. Tossavainen, T. Palmen, P. Kulmala, M. Knip, and H. Holthofer Circulating antibodies to nephrin in patients with type 1 diabetes Nephrol. Dial. Transplant., January 1, 2007; 22(1): 146 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xing, J. Ding, Q. Fan, and N. Guan Diversities of Podocyte Molecular Changes Induced by Different Antiproteinuria Drugs. Experimental Biology and Medicine, May 1, 2006; 231(5): 585 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Awad, L. Huang, H. Ye, E. T. A. Duong, W. K. Bolton, J. Linden, and M. D. Okusa Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy Am J Physiol Renal Physiol, April 1, 2006; 290(4): F828 - F837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J N Jensen, L. Denner, B. F Schrijvers, R. G Tilton, R. Rasch, and A. Flyvbjerg Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol., March 1, 2006; 188(3): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Liebau, D. Lang, J. Bohm, N. Endlich, M. J. Bek, I. Witherden, P. W. Mathieson, M. A. Saleem, H. Pavenstadt, and K.-G. Fischer Functional expression of the renin-angiotensin system in human podocytes Am J Physiol Renal Physiol, March 1, 2006; 290(3): F710 - F719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nakhoul, R. Ramadan, E. Khankin, A. Yaccob, Z. Kositch, M. Lewin, S. Assady, and Z. Abassi Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies Am J Physiol Renal Physiol, October 1, 2005; 289(4): F880 - F890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wolf, S. Chen, and F. N. Ziyadeh From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease: Podocyte Injury Comes of Age in Diabetic Nephropathy Diabetes, June 1, 2005; 54(6): 1626 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J Kelly, Y. Zhang, R. M Gow, S. Itescu, and R. E Gilbert Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 76 - 80. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Kelly, Y. Zhang, R. Gow, and R. E. Gilbert Tranilast Attenuates Structural and Functional Aspects of Renal Injury in the Remnant Kidney Model J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2619 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kelly, A. J. Cox, R. M. Gow, Y. Zhang, B. E. Kemp, and R. E. Gilbert Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In Vivo Hypertension, August 1, 2004; 44(2): 195 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Langham, D. J. Kelly, A. J. Cox, R. M. Gow, H. Holthofer, and R. E. Gilbert Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin Nephrol. Dial. Transplant., January 1, 2004; 19(1): 262 - 263. [Full Text] [PDF]
|
|
|
|
|
|
A. Patari, C. Forsblom, M. Havana, H. Taipale, P.-H. Groop, and H. Holthofer Nephrinuria in Diabetic Nephropathy of Type 1 Diabetes Diabetes, December 1, 2003; 52(12): 2969 - 2974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Doublier, G. Salvidio, E. Lupia, V. Ruotsalainen, D. Verzola, G. Deferrari, and G. Camussi Nephrin Expression Is Reduced in Human Diabetic Nephropathy: Evidence for a Distinct Role for Glycated Albumin and Angiotensin II Diabetes, April 1, 2003; 52(4): 1023 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mundel and S. J. Shankland Podocyte Biology and Response to Injury J. Am. Soc. Nephrol., December 1, 2002; 13(12): 3005 - 3015. [Full Text] [PDF]
|
|